糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗(Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate) - 药物靶点：GR x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor_在研适应症：哮喘，慢性支气管炎，慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Closed Triple、Elebrato Ellipta、FF/UMEC/VI

+ [19]

靶点

GR x M1 receptor x M2 receptor x M3 receptor x M4 receptor x M5 receptor x β2-adrenergic receptor

作用方式

激动剂、拮抗剂

作用机制

GR激动剂(糖皮质激素受体激动剂)、M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)

治疗领域

免疫系统疾病感染呼吸系统疾病

在研适应症

哮喘慢性支气管炎慢性阻塞性肺疾病+ [1]

非在研适应症

心血管疾病冠状动脉疾病高血压+ [4]

原研机构

GSK Plc

在研机构

GlaxoSmithKline Trading Services Ltd.GlaxoSmithKline Intellectual Property Development Ltd.GlaxoSmithKline, Inc.

+ [3]

非在研机构

Glaxo Group Ltd.

葛兰素史克（中国）投资有限公司

权益机构

Royalty Pharma Plc

Theravance Biopharma, Inc.

Innoviva, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2017-09-18),

慢性阻塞性肺疾病

最高研发阶段(中国)批准上市

特殊审评特殊审批 (中国)

登录后查看时间轴

结构/序列

分子式C44H49Cl2NO7

InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N

CAS号503070-58-4

查看全部结构式(3)

关联

43

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的临床试验

NCT06905483

/ Recruiting临床4期IIT

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs.
The main questions it aims to answer are:
* Does BGF demonstrate a comparable effect to FUV in COPD participants?
* What medical problems do participants experience when taking BGFand FUV?

开始日期2025-04-01

申办/合作机构

Thammasat University

NCT06474039

/ Recruiting临床3期IIT

The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD

This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators

开始日期2024-10-01

申办/合作机构

Mahidol University

NCT06372496

/ Active, not recruiting临床4期

A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

开始日期2024-04-16

申办/合作机构

GSK Plc

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的临床结果

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的转化医学

登录后查看更多信息

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的专利（医药）

登录后查看更多信息

21

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的文献（医药）

2025-07-01·Respiratory Investigation

Analysis of adherence to ICS/LAMA/LABA in patients with asthma: a retrospective observational cohort study using medical claims data

Article

作者: Yarita, Masao ; Oga, Toru ; Ito, Risako ; Mukai, Isao ; Requena, Gema ; Mita, Chifuku ; Takano, Masashi

BACKGROUND:

Real-world evidence of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) use in Japan is limited. This real-world study assessed adherence to FF/UMEC/VI once-daily single-inhaler triple therapy (SITT) versus multiple-inhaler triple therapy (MITT) among patients with asthma in Japan.

METHODS:

Retrospective observational cohort study of patients with asthma initiating FF/UMEC/VI SITT or MITT, using claims data (02/18/2021-02/28/2022, JMDC database). Patients were aged ≥15 years at index (date of FF/UMEC/VI or MITT claim). Outcomes were assessed in two cohorts and weighted using inverse probability of treatment weighting: 1) 'overall cohort' included patients who received FF/UMEC/VI or MITT as initial maintenance therapy (IMT) or as non-IMT (i.e., had previously received inhaled corticosteroid-containing medication during baseline); 2) 'non-IMT cohort' was a sub-cohort of the overall cohort.

PRIMARY OUTCOME:

proportion of adherent patients (proportion of days covered ≥0.8) in the 3, 6, and 12 months after, and including, index date.

RESULTS:

The overall cohort comprised 7228 (FF/UMEC/VI) and 864 (MITT) patients. Of these, 3623 and 735 were included in the FF/UMEC/VI and MITT non-IMT cohort, respectively. At 3 months post-index, a significantly higher proportion of patients were adherent to FF/UMEC/VI (36.4 % [n = 2631]) versus MITT (31.2 % [n = 270]) in the overall cohort (rate ratio [95 % confidence interval], 1.16 [1.05-1.29], p = 0.003, weighted), and FF/UMEC/VI (36.6 % [n = 1326]) versus MITT (28.9 % [n = 213]) in the non-IMT cohort (1.26 [1.12-1.43], p < 0.001). Similar results were observed at 6, and 12 months post-index.

CONCLUSIONS:

Patients with asthma in Japan who initiated FF/UMEC/VI SITT had significantly better treatment adherence than those who initiated MITT.

2025-03-01·Pulmonary Therapy

Retrospective Cohort Study of Elderly Users of Single- or Multiple-Inhaler Triple Therapy for the Treatment of Asthma in the USA

Article

作者: Laliberté, Francois ; Paczkowski, Rosirene ; Burrows, Emmeline ; Duh, Mei Sheng ; Mahendran, Malena ; Settipane, Russell A ; Germain, Guillaume ; Hilts, Annalise

INTRODUCTION:

Escalation to single- or multiple-inhaler triple therapy (SITT; MITT) is a recommended option for patients with asthma who remain uncontrolled by medium-dose inhaled corticosteroid/long-acting β₂-agonist; however, characterization of elderly users of triple therapy is limited. This real-world cohort study describes demographics and clinical characteristics of elderly patients with asthma with and without comorbid chronic obstructive pulmonary disease (COPD) who are new users of triple therapy, and asthma treatment patterns preceding triple therapy initiation.

METHODS:

This retrospective cohort study used administrative claims data from the Optum Clinformatics Data Mart database. Eligible patients were ≥ 65 years of age with asthma or with asthma and comorbid COPD who initiated either triple therapy with single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; 100/62.5/25 μg) or MITT between September 18, 2017 and September 30, 2020. Demographics, clinical characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns were described in the 12-month period before triple therapy initiation (baseline period).

RESULTS:

In total, 15,557 patients were included. Among FF/UMEC/VI initiators with asthma (N = 635) mean age was 73.3 years and 66.6% were female. During the baseline period, > 75% of patients used controller therapy, > 92% used rescue medications, 27.9% experienced ≥ 1 asthma-related exacerbation, with mean annual exacerbation rate of 0.42, and mean all-cause healthcare costs were $23,407. Patients with asthma initiating MITT and patients with asthma and comorbid COPD initiating FF/UMEC/VI or MITT had similar characteristics, healthcare resource utilization, healthcare costs, and asthma treatment patterns to FF/UMEC/VI initiators with asthma.

CONCLUSIONS:

Triple therapy is often initiated following use of other asthma controller medications in real-world practice. Substantial rescue medication use and high disease and economic burden among this elderly patient population suggest that their asthma was not adequately controlled prior to triple therapy initiation. This retrospective study provides an early profile of elderly patients with asthma in the USA.

2025-02-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Effect of non-spherical shape of dry powder aerosol drugs on their airway deposition distribution

Article

作者: Ambrus, R ; Nagy, A ; Farkas, Á ; Kolonits, T ; Kugler, Sz ; Füri, P ; Horváth, A ; Kheirandish, S

In the majority of aerosol drug deposition modelling efforts, the particles are approximated by regular spheres. However, microscope images acquired after drug formulation available in the open literature suggest that their shape is not regular in most of the cases. This work aimed to combine experimental measurements and numerical simulations to reveal the shape factors of the particles of commercialized aerosol drugs and the effect of non-sphericity on the lung deposition distribution of these drugs. Aerosol particles of Bretaris® Genuair®, Buventol® Easyhaler® and Trelegy® Ellipta® were collected on the stages of a Next Generation Impactor after their emission from the dry powder inhalers. The samples were analyzed using scanning electron microscopy techniques. Aspect ratios and dynamic shape factors characteristic of particles in the size fractions representing each impactor stage were determined. Computer modelling of their airway deposition was performed by both neglecting and considering their irregular shape. The results of particle size measurements revealed that there was no size-specific shape factor of the particles, as they could be well characterized by a global shape factor. Although there was some inter-drug difference in terms of shape factors, the values were quite close to unity (usually between 1.02 and 1.06), except for the fiber-shaped particles representing a minority in the composition of Trelegy® Ellipta®, which could be characterized by shape factors of around 1.6. The results of computer simulations of deposition distribution indicate that neglecting the irregular shape does not lead to a major distortion of the simulation results unless fiber-shaped particles are also present after the formulation.

90

项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的新闻（医药）

2025-05-13

·ETPharma

GSK Indian arm FY25 net profit soars 32% to ₹915 crore

New Delhi: UK-pharma major GlaxoSmithKline (GSK) Indian arm ended the fiscal year 2024-25 with a gross revenue of ₹3,723 crore and a net profit of ₹915 crore. Over the financial year the company’s revenue reported an uptick of 9 per cent whereas the net profit went up by 32 per cent against the previous fiscal. During the period the drugmaker's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) margin stood at 31.4 per cent. Commenting on the results, Bhushan Akshikar, MD GSK Pharmaceuticals Limited, said, “Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration.” As per the MD key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a major role in driving growth throughout the year. For the quarter ended March 31, 2025, on a year-on-year (YoY) basis the company revenue went up 6 per cent to ₹966 crore, and the Profit After Tax (PAT) touched ₹260 crores. Over the company’s future plans Akshikar shared that, “we will continue to focus on our innovative portfolio through the launch of our oncology assets.” The company is progressing to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer, the release stated. Following the announcement of results the board of directors have recommended a final dividend of ₹42 per equity share. By Online Bureau ,

上市批准财报免疫疗法生物类似药

2025-05-06

·CPHI制药在线

阿斯利康哮喘三联疗法获批倒计时，哮喘治疗迈入新纪元！

关注并星标CPHI制药在线哮喘作为一种全球性慢性呼吸道疾病，影响着约2.62亿人，其中近半数患者即便接受双重疗法（ICS/LABA）仍无法有效控制病情，导致肺功能下降和生活质量恶化。2025年5月2日，阿斯利康宣布其固定剂量三联疗法Breztri Aerosphere在两项III期临床试验（KALOS和LOGOS）中取得突破性成果，为哮喘治疗领域注入新希望（图1）。1、从COPD到哮喘的机制优势Breztri Aerosphere由吸入糖皮质激素（布地奈德）、长效抗胆碱药（格隆溴铵）和长效β2受体激动剂（福莫特罗）组成，通过协同作用抑制气道炎症、舒张支气管平滑肌，并减少黏液分泌。此前，该药已在全球50多个国家获批用于慢性阻塞性肺病（COPD）的维持治疗，显著降低急性加重率24%。此次针对哮喘的III期研究成功，标志着其适应症从COPD向哮喘的扩展迈出关键一步。图1.阿斯利康两项哮喘III期研究成功KALOS和LOGOS研究采用随机、双盲设计，纳入约4400例未控哮喘患者，旨在评估Breztri作为潜在哮喘治疗方法，对比维持ICS/LABA治疗在成人和青少年未控哮喘患者中的疗效和安全性。结果显示：与 ICS/LABA 双重联合疗法相比，三联疗法在FEV1（第1秒用力呼气容积）的曲线下面积（AUC0-3）和谷值FEV1上均显著优于对照组，BREZTRI 在改善患者肺功能方面，具有统计学意义和临床意义上的显著优势。具有统计学和临床双重意义；且未发现新的安全性信号，常见不良反应（如上呼吸道感染、咳嗽）与既往COPD研究一致，发生率可控。阿斯利康研发负责人Sharon Barr强调，Breztri的哮喘数据建立在COPD应用的成熟基础上，有望覆盖更广泛患者群体。意大利呼吸医学专家Alberto Papi指出，三联疗法或将成为未控哮喘患者的"变革性选择"，填补双联疗法的疗效缺口（图1）。2、从COPD基础到哮喘蓝海根据国家呼吸医学中心最新流行病学数据，支气管哮喘和慢性阻塞性肺疾病（COPD）已成为我国重大公共卫生问题。在哮喘领域，流行病学调查显示我国现存确诊患者逾5300万例，其中成人（≥18岁）患病率达4.2%，而儿童群体（0-17岁）发病率3.07%，对应760万患儿人群。尤其值得注意的是，城市地区存在显著诊疗缺口：约30%的儿童哮喘未能实现早期诊断，且有超过20%的确诊患儿未达GINA指南推荐的控制标准，凸显临床规范化管理的迫切需求。在慢阻肺疾病负担方面，全国多中心研究数据显示，我国20岁以上成年人COPD标化患病率为8.6%，该比例在40岁以上人群中陡增至13.7%，据此测算全国患者基数已逼近1亿例。年龄相关性发病特征提示，随着人口老龄化加剧，疾病防控将面临更大挑战。市场维度分析显示，呼吸系统用药领域展现出强劲发展韧性。尽管受新冠疫情防控政策调整、国家集采常态化等宏观因素影响，哮喘/COPD药物市场仍保持11.7%的年复合增长率，2023年整体规模突破250亿元。特别值得关注的是，在带量采购政策实施后，部分原研品种通过差异化竞争策略实现逆势增长，年度同比增幅达24%（图2），印证了该领域持续存在的刚性临床需求与市场创新活力。图2.哮喘/COPD药物销售额年度趋势Breztri已在COPD领域奠定坚实基础，ETHOS和KRONOS试验显示，其降低COPD急性加重率24%，并改善肺功能。自2020年起，该药陆续在美国、欧盟、中国和日本获批，全球覆盖超80个国家。现有双联疗法存在近50%患者症状反复的局限性，亟需更高效方案。当前哮喘生物制剂（如抗IgE、抗IL-5药物）主要针对特定表型患者，而Breztri作为广谱吸入疗法，适用人群更广泛。若获批哮喘适应症，其市场容量有望从COPD患者扩展至哮喘人群，形成双重增长引擎。阿斯利康通过吸入剂（如Breztri）与生物制剂（如Fasenra、Tezspire）的组合，构建了覆盖轻中重度患者的全病程解决方案。Fasenra可靶向嗜酸性粒细胞，而Breztri提供即时症状控制，形成差异化优势。这种吸入与生物的综合策略，强化了阿斯利康在呼吸领域的领导地位。3、从监管审批到临床应用尽管Breztri Aerosphere的III期临床试验数据展现出对未控哮喘患者的显著疗效，但其从监管审批到临床普及仍需跨越多重障碍。虽然KALOS和LOGOS研究显示Breztri未出现新的安全性信号，但其哮喘适应症的获批仍需通过各国监管机构的严格审查。以美国FDA为例，其曾明确警示长效β2受体激动剂（LABA）单药治疗哮喘可能增加死亡风险，这一历史性警示可能影响审批决策。不过，Breztri因包含吸入糖皮质激素（ICS）成分，其安全性数据可能更具说服力--已有研究表明，ICS与LABA联用可降低严重哮喘事件风险，这一机制或成为突破审批的关键。此外，价格则是另一大壁垒。Breztri当前在COPD领域的定价较高，若哮喘适应症维持相近水平，将显著高于传统ICS/LABA疗法，可能限制其在低收入国家的普及。而GSK的Trelegy因被纳入美国医保谈判名单，2027年价格或大幅下降，进一步挤压Breztri的市场空间。阿斯利康需通过差异化策略提升可及性，但其成本控制能力将面临考验。值得注意的是，阿斯利康正在通过适应症扩展构建产品护城河。Breztri已在COPD领域覆盖80余国，若哮喘适应症获批，可借助现有渠道快速铺开，形成呼吸疾病全周期管理矩阵。然而，这一战略的成功与否，最终取决于监管机构对跨适应症协同价值的认可，以及医保支付方对"高定价-广覆盖"商业模式的容忍度。结语Breztri Aerosphere的III期成功是阿斯利康在哮喘领域的又一的里程碑事件，标志着哮喘治疗从"控制症状"向"疾病缓解"的范式转变。其依托COPD市场的先发优势，有望在哮喘领域开辟新蓝海。未来，随着后续研究数据的积累和适应症拓展，Breztri或将成为呼吸疾病领域的重磅药物，为全球数亿患者提供更优解。参考资料 [1] https://www.astrazeneca-us.com/media/press-releases/2025/Breztri-met-primary-endpoints-in-kalos-and-logos-phase-III-trials-in-asthma.html [2] 第三次中国城市儿童哮喘流行病学调查[J].中华儿科杂志,2013年 [3] 支气管哮喘防治指南（2020年) [4] 中国慢性阻塞性肺疾病基层诊疗与管理指南（2024年）END【企业推荐】领取CPHI & PMEC China 2025展会门票来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床3期临床结果

2025-05-02

·FiercePharma

AstraZeneca's Breztri aces 2 asthma trials, lining it up for label expansion

AstraZeneca's inhaler Breztri Aerosphere, which was approved for COPD in 2020, has taken a step toward a label expansion as it has aced two asthma trials. AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.Two phase 3 trials evaluating the effectiveness and safety of Breztri in a total of 4,434 patients with uncontrolled asthma have met their primary endpoints. The studies showed that Breztri delivered statistically significant and clinically meaningful improvements in lung function compared to dual-drug combinations of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) maintenance treatments, AZ said.Data from the KALOS and LOGOS studies will be shared with regulatory authorities and presented at an upcoming medical meeting, the company added.Breztri Aerosphere, which was approved for chronic obstructive pulmonary disorder (COPD) in 2020, is a fixed-dose combination of the corticosteroid budesonide, the LABA formoterol fumarate and the long-acting muscarinic antagonist (LAMA) glycopyrronium.With sales (PDF) of $300 million in the first quarter of 2025, an increase of 37% year over year, Breztri is on its way to blockbuster status for the first time this year.A label expansion to treat asthma would open the treatment up to another large patient population. The condition affects roughly 262 million people around the world, AZ said, with nearly half of those treated with dual therapies remaining uncontrolled. “Despite advancements in asthma treatments, millions of patients remain uncontrolled, which can cause frequent breathlessness, coughing and wheezing,” Alberto Papi, of the St. Anna University Hospital in Ferrara, Italy, said in a press release. “The results from the KALOS and LOGOS trials are exciting and demonstrate the potential of Breztri to evolve the standard of care to more effectively treat asthma in a single inhaled triple therapy.”Breztri was developed as a combination of AZ’s blockbuster Symbicort (budesonide/formoterol), which was approved for asthma in 2006, and Bevespi (formoterol fumarate/glycopyrrolate), which was approved for COPD in 2016. In its development, Breztri has trailed GSK’s triple therapy Trelegy Ellipta, which was approved for COPD in 2017 and for asthma in 2020. Trelegy generated sales of $3.5 billion in 2024, an increase of 26%. GlobalData forecasts that sales of Breztri will reach $2.3 billion in 2030.Breztri is one of several treatments AZ is developing for respiratory diseases, including Fasenra and Amgen-partnered Tezspire. Both of those drugs have been approved to treat asthma and AZ is eying potential COPD label expansions. Fasenra achieved sales of $1.7 billion last year. AZ reported sales for fast-rising Tezspire, which was approved in 2021, at $684 million.

临床结果上市批准临床3期

100 项与糠酸氟替卡松/乌美溴铵/三苯乙酸维兰特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL08	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	加拿大	GlaxoSmithKline, Inc.	2018-05-30
慢性支气管炎	加拿大	GlaxoSmithKline, Inc.	2018-04-04
慢性阻塞性肺疾病	美国	GlaxoSmithKline Intellectual Property Development Ltd.	2017-09-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性哮喘	临床3期	美国	GSK Plc	2023-04-24
急性哮喘	临床3期	澳大利亚	GSK Plc	2023-04-24
心血管疾病	临床3期	美国	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	美国	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	日本	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	日本	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	阿根廷	葛兰素史克（中国）投资有限公司	2012-01-25
心血管疾病	临床3期	阿根廷	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	澳大利亚	Glaxo Group Ltd.	2012-01-25
心血管疾病	临床3期	澳大利亚	葛兰素史克（中国）投资有限公司	2012-01-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2025	N/A	哮喘	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	廠鑰選壓壓衊遞蓋簾廠(襯鏇膚糧築遞襯鏇鹽餘) = 簾夢餘簾齋獵網觸鏇淵艱膚衊簾淵觸窪醖獵廠 (膚鬱繭選淵積繭餘廠繭, 0.70[0.69 ~ 0.72]) 更多	积极	2025-05-16
ATS2025	临床3期	慢性阻塞性肺疾病 St George's Respiratory Questionnaire (SGRQ)-C questions 1 (cough)	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	網艱醖鏇醖製壓鏇齋觸(製糧夢鏇鑰築蓋窪觸襯) = 構蓋製廠鏇獵鏇餘鬱壓襯醖繭願餘鏇蓋醖鹽餘 (製淵齋鹽齋網夢鏇壓鬱 )	积极	2025-05-16
				Budesonide/Formoterol (BUD/FOR)	網艱醖鏇醖製壓鏇齋觸(製糧夢鏇鑰築蓋窪觸襯) = 襯憲鹹選願廠膚膚鹽選襯醖繭願餘鏇蓋醖鹽餘 (製淵齋鹽齋網夢鏇壓鬱 )
NCT04923347 (CTgov)	临床4期	慢性阻塞性肺疾病	229	fluticasone furoate+vilanterol+umeclidinium	觸餘製鏇鏇繭鹹網餘範 = 製獵觸淵鹽網積艱網鹹遞選廠膚遞糧淵窪簾範 (願艱製蓋廠憲鏇簾獵選, 壓顧範糧選餘襯鏇鑰糧 ~ 襯餘獵襯齋積壓鏇網鏇) 更多	-	2025-03-24
NCT05535972 (CTgov)	临床4期	慢性阻塞性肺疾病	463	fluticasone furoate+vilanterol+Trelegy+umeclidinium	壓鬱遞獵築餘醖觸鏇蓋(簾鏇鹹壓構糧窪壓襯衊) = 糧窪簾淵鹽餘獵夢齋膚遞觸膚窪繭選艱鹹壓範 (膚顧願餘蓋繭蓋餘選醖, 5.49) 更多	-	2024-11-04
ATS2024	N/A	慢性阻塞性肺疾病 \| 哮喘	-	FF/UMEC/VI-100	積糧製繭齋膚鹹鑰積鹽(鏇範廠齋窪網網鑰製選) = 醖夢願醖願醖鏇鬱範獵糧鬱鹽選襯鏇獵鹹醖選 (餘蓋簾壓廠窪淵網壓鏇 ) 更多	-	2024-05-19
				FF/UMEC/VI-200	積糧製繭齋膚鹹鑰積鹽(鏇範廠齋窪網網鑰製選) = 遞築製淵構餘憲鬱夢鹽糧鬱鹽選襯鏇獵鹹醖選 (餘蓋簾壓廠窪淵網壓鏇 ) 更多
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	顧憲網蓋遞夢膚夢壓艱(獵廠遞膚觸繭鑰簾壓鑰) = 遞憲襯鬱遞獵顧蓋遞夢糧範繭膚鏇膚繭憲衊醖 (壓壓蓋鏇夢構遞艱鑰鏇 )	-	2024-05-19
				Budesonide/Glycopyrrolate/Formoterol Fumarate (BUD/GLY/FORM)	顧憲網蓋遞夢膚夢壓艱(獵廠遞膚觸繭鑰簾壓鑰) = 繭願觸醖淵蓋構膚構艱糧範繭膚鏇膚繭憲衊醖 (壓壓蓋鏇夢構遞艱鑰鏇 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Prompt initiation of FF/UMEC/VI	獵遞壓積鹹齋鏇蓋鹹餘(簾築壓獵鹹網築積獵艱) = 淵範鹹鹽夢鹽繭遞膚壓窪鬱製廠獵壓蓋顧壓鏇 (獵觸鑰壓壓衊淵壓餘簾 ) 更多	积极	2024-05-19
				Delayed initiation of FF/UMEC/VI	獵遞壓積鹹齋鏇蓋鹹餘(簾築壓獵鹹網築積獵艱) = 艱衊遞構觸窪觸襯鑰遞窪鬱製廠獵壓蓋顧壓鏇 (獵觸鑰壓壓衊淵壓餘簾 ) 更多
NCT02924688 (CAPTAIN, ATS2024)	临床3期	哮喘维持	-	FF/UMEC/VI 100/62.5/25mcg	膚憲鏇夢選繭鬱餘觸淵(築蓋醖蓋壓積蓋顧膚鑰) = 廠觸築鹹積鹽積簾廠獵壓鬱繭鬱鬱鹹鹹醖製衊 (衊憲製積鹽積餘繭衊積 )	-	2024-05-19
				FF/UMEC/VI 200/62.5/25mcg	膚憲鏇夢選繭鬱餘觸淵(築蓋醖蓋壓積蓋顧膚鑰) = 積願醖製餘鹹膚獵廠艱壓鬱繭鬱鬱鹹鹹醖製衊 (衊憲製積鹽積餘繭衊積 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol	觸鹹遞衊鑰觸艱觸觸齋(夢鏇網願蓋築築廠構蓋) = 憲顧壓夢選積膚簾觸齋鑰窪獵鏇鬱憲廠選繭獵 (構築構窪襯範鬱廠遞餘 )	-	2024-05-19
				Budesonide/Formoterol	觸鹹遞衊鑰觸艱觸觸齋(夢鏇網願蓋築築廠構蓋) = 鏇鑰簾鹽衊鑰積憲糧齋鑰窪獵鏇鬱憲廠選繭獵 (構築構窪襯範鬱廠遞餘 )
NCT04651777 (ETHA, CTgov)	临床3期	哮喘	31	FF/UMEC/VI	衊膚齋觸襯艱糧製夢膚(醖膚衊膚簾網範鹹選鹽) = 觸積夢壓夢構築艱廠範範鏇憲廠餘鏇顧鬱築鹽 (選願願廠積餘夢醖願淵, 12) 更多	-	2024-03-29